MedTrace Logo

Neoadjuvant Chemotherapy in Breast Cancer

NCT04802941 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2021-03-18

No results posted yet for this study

Summary

This study compares two approaches of upfront chemotherapy in breast cancer.

Conditions

  • Decision Support Systems, Clinical

Interventions

DEVICE

Neoadjuvant Chemotherapy by CDSS (MedicBK)

CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.

DRUG

General practice

General practice

Sponsors & Collaborators

  • Center for New Medical Technologies, Novosibirsk, Russia

    collaborator OTHER

  • I.M. Sechenov First Moscow State Medical University

    collaborator OTHER

  • Novosibirsk Oncology Center

    collaborator UNKNOWN

  • Center of Personalized Medicine, Pirogova

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2024-03-30
Completion
2024-03-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04802941 on ClinicalTrials.gov